Abstract
Monoclonal antibodies that effectively neutralize HIV-1 have been widely sought, yet few have been isolated. Now, technological advances in sera evaluation, B cell stimulation, microneutralization, and antibody cloning have allowed Burton and colleagues to identify two broadly neutralizing monoclonal antibodies, PG9 and PG16, which provide insights for HIV vaccine design.
Original language | English (US) |
---|---|
Pages (from-to) | 292-294 |
Number of pages | 3 |
Journal | Cell Host and Microbe |
Volume | 6 |
Issue number | 4 |
DOIs | |
State | Published - Nov 22 2009 |
Externally published | Yes |
ASJC Scopus subject areas
- Immunology and Microbiology(all)
- Cancer Research
- Molecular Biology